CUAMC
China Universal Asset Management Company Portfolio holdings
AUM
$1.06B
1-Year Return
31.81%
This Quarter Return
-2.22%
1 Year Return
+31.81%
3 Year Return
+205.04%
5 Year Return
–
10 Year Return
–
AUM
$1.07B
AUM Growth
+$5.91M
(+0.55%)
Cap. Flow
+$63.5M
Cap. Flow
% of AUM
5.91%
Top 10 Holdings %
Top 10 Hldgs %
36.46%
Holding
509
New
13
Increased
172
Reduced
270
Closed
23
Top Buys
| 1 |
Apple
AAPL
|
$12.2M |
| 2 |
Amazon
AMZN
|
$8.41M |
| 3 |
Microsoft
MSFT
|
$6.53M |
| 4 |
Analog Devices
ADI
|
$4.63M |
| 5 |
Alphabet (Google) Class A
GOOGL
|
$3.68M |
Top Sells
| 1 |
iShares Silver Trust
SLV
|
$7.9M |
| 2 |
ProShares Ultra Gold
UGL
|
$7.89M |
| 3 |
Arista Networks
ANET
|
$6.7M |
| 4 |
Gilead Sciences
GILD
|
$5.26M |
| 5 |
TSMC
TSM
|
$3.61M |
Sector Composition
| 1 | Technology | 36.93% |
| 2 | Healthcare | 24.36% |
| 3 | Consumer Discretionary | 11.82% |
| 4 | Communication Services | 11.17% |
| 5 | Consumer Staples | 4.05% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
401
Astria Therapeutics
ATXS
$397M
| $60.4K | 0.01% |
11,320
-646
| -5% | -$3.45K |
|
402
Aura Biosciences
AURA
$399M
| $58.7K | 0.01% |
10,019
-573
| -5% | -$3.36K |
|
403
OmniAb
OABI
$233M
| $58.3K | 0.01% |
24,273
-1,386
| -5% | -$3.33K |
|
|
ALMS
404
Alumis Inc. Common Stock
ALMS
$472M
| $58.2K | 0.01% |
9,472
-541
| -5% | -$3.32K |
|
405
Absci
ABSI
$354M
| $57.8K | 0.01% |
23,038
-1,316
| -5% | -$3.3K |
|
406
MaxCyte
MXCT
$145M
| $57.8K | 0.01% |
21,158
-1,208
| -5% | -$3.3K |
|
407
Arcturus Therapeutics
ARCT
$470M
| $57.5K | 0.01% |
5,433
-311
| -5% | -$3.29K |
|
408
ChargePoint
CHPT
$238M
| $57.5K | 0.01% |
4,750
| – | – |
|
409
Monte Rosa Therapeutics
GLUE
$303M
| $57.2K | 0.01% |
12,323
-704
| -5% | -$3.27K |
|
410
Taysha Gene Therapies
TSHA
$887M
| $57.2K | 0.01% |
41,120
-2,336
| -5% | -$3.25K |
|
411
Esperion Therapeutics
ESPR
$530M
| $56.9K | 0.01% |
39,522
-2,257
| -5% | -$3.25K |
|
412
Solid Biosciences
SLDB
$426M
| $56.6K | 0.01% |
15,308
+6,836
| +81% | +$25.3K |
|
413
Olema Pharmaceuticals
OLMA
$478M
| $56K | 0.01% |
14,892
+2,743
| +23% | +$10.3K |
|
414
Alpha Teknova
TKNO
$227M
| $55.5K | 0.01% |
10,693
-610
| -5% | -$3.17K |
|
415
Vanda Pharmaceuticals
VNDA
$274M
| $53.7K | 0.01% |
11,697
-666
| -5% | -$3.06K |
|
416
Aquestive Therapeutics
AQST
$629M
| $53K | ﹤0.01% |
18,289
-1,044
| -5% | -$3.03K |
|
|
TECX
417
Tectonic Therapeutic, Inc. Common Stock
TECX
$335M
| $52.4K | ﹤0.01% |
2,959
-169
| -5% | -$2.99K |
|
418
Prime Medicine
PRME
$628M
| $52.4K | ﹤0.01% |
26,309
-1,502
| -5% | -$2.99K |
|
|
TSVT
419
DELISTED
2seventy bio
TSVT
| $51.1K | ﹤0.01% |
10,348
-591
| -5% | -$2.92K |
|
420
Atea Pharmaceuticals
AVIR
$262M
| $50.7K | ﹤0.01% |
16,942
-967
| -5% | -$2.89K |
|
|
SLRN
421
DELISTED
ACELYRIN
SLRN
| $49.9K | ﹤0.01% |
20,199
-1,074
| -5% | -$2.65K |
|
422
Ironwood Pharmaceuticals
IRWD
$184M
| $47.2K | ﹤0.01% |
32,099
-1,833
| -5% | -$2.7K |
|
423
Terns Pharmaceuticals
TERN
$611M
| $47K | ﹤0.01% |
17,037
-973
| -5% | -$2.69K |
|
424
Codexis
CDXS
$219M
| $44.7K | ﹤0.01% |
16,616
-639
| -4% | -$1.72K |
|
425
Humacyte
HUMA
$223M
| $44K | ﹤0.01% |
25,809
-1,473
| -5% | -$2.51K |
|